Ningxia Medical University
13
3
4
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
Role: collaborator
Artificial Intelligence-assisted Diagnosis
Role: collaborator
Correcting Myopia Among Secondary School Children to Increase Academic High School Attendance Rates in Rural Communities
Role: collaborator
Normal Reference Range for Neonatal Echocardiography
Role: collaborator
Prevalence and Risk Indicators of Peri-implant Diseases in China
Role: collaborator
NUTS for the Prevention of Cardiovascular Disease in Chinese Adults
Role: collaborator
Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma
Role: collaborator
China Salt Substitute and Stroke Study
Role: collaborator
Application of Deep-learning and Ultrasound Elastography in Opportunistic Screening of Breast Cancer
Role: collaborator
A National School-based Health Lifestyles Interventions Among Chinese Children and Adolescents Against Obesity
Role: collaborator
Evaluation of the Factors Affecting the Diagnostic Performance of Coronary Computed Tomography Angiogram (CTA) With Multi-slice Computed Tomography (MSCT)
Role: collaborator
Clinical Values of Dose Reduction Techniques in Computed Tomography (CT) Coronary Artery Imaging With 64-row Multi-Slice Helical CT
Role: collaborator
Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)
Role: collaborator
All 13 trials loaded